VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Submission of Matters to a Vote of Security Holders

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.

Story continues below

On September 14, 2018, VistaGen Therapeutics, Inc. (the“Company”) held its 2018 Annual Meeting of Stockholders (the“Annual Meeting”). The matters voted upon at the Annual Meeting and the results of the voting are set forth below.

Proposal No. 1- Election of Directors

Director Nominees

For

Withheld

Jon S. Saxe

4,915,906

97,194

Shawn K. Singh

4,899,517

113,583

H. Ralph Snodgrass

4,885,209

127,891

Brian J. Underdown

4,876,074

137,026

Jerry B. Gin

4,852,173

160,927

The Company’s Directors are elected by the affirmative vote of a plurality of the votes cast. Accordingly, the Company's stockholders elected each of the nominees named above to serve on the Company's Board of Directors until the 2019 Annual Meeting of Stockholders, or until their successors are elected and qualified.

Proposal No. 2- Ratification of Appointment of Auditors

For

Against

Abstain

15,901,502

902,448

208,892

The vote required to approve this proposal was the affirmative vote of a majority of the votes cast on the proposal. Accordingly, stockholders ratified the appointment of OUM & Co, LLP as the Company’s registered independent public accounting firm for the fiscal year ending March 31, 2019.

For more information about the foregoing proposals, please review the Company’s definitive proxy statement, filed with the Securities and Exchange Commission on July 27, 2018.

Item 7.01Regulation FD Disclosure.

On September 14, 2018, the Company utilized a new corporate presentation at the Annual Meeting (the “Corporate Presentation”). A copy of the Corporate Presentation is attached hereto as Exhibit99.1.

The information in this Item 7.01 of this Current Report onForm8-K,including the information set forth in Exhibit99.1, is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

In addition, this Current Report on Form 8-K and the exhibit(s) attached hereto may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) statements with respect to the Company's plans, objectives, expectations and intentions; and (ii) other statements identified by words such as "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties.

Item 9.01 Exhibits.

See Exhibit Index.


VistaGen Therapeutics, Inc. Exhibit

To view the full exhibit click here

About VistaGen Therapeutics, Inc. (NASDAQ:VTGN)

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.

An ad to help with our costs